Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
Subscribe To Our Newsletter & Stay Updated